Results 1 to 10 of about 5,878 (137)

Effects of abciximab on key pattern of human coronary restenosis in vitro: impact of the SI/MPL-ratio [PDF]

open access: yesBMC Cardiovascular Disorders, 2006
Background The significant reduction of angiographic restenosis rates in the ISAR-SWEET study (intracoronary stenting and antithrombotic regimen: is abciximab a superior way to eliminate elevated thrombotic risk in diabetes) raises the question of ...
Rainer Voisard   +46 more
core   +4 more sources

Eptifibatide and abciximab inhibit insulin-induced focal adhesion formation and proliferative responses in human aortic smooth muscle cells [PDF]

open access: yesCardiovascular Diabetology, 2008
Background The use of abciximab (c7E3 Fab) or eptifibatide improves clinical outcomes in diabetics undergoing percutaneous coronary intervention. These β3 integrin inhibitors antagonize fibrinogen binding to αIIbβ3 integrins on platelets and ligand ...
Alokkumar Pathak   +3 more
core   +4 more sources

Intracoronary versus intravenous administration of abciximab in patients with acute coronary syndrome: a meta-analysis. [PDF]

open access: yesPLoS ONE, 2013
BACKGROUND: Abciximab is a widely used adjunctive therapy for acute coronary syndrome (ACS). However, the effect of intracoronary (i.c.) administration of abciximab on cardiovascular events remains unclear when compared with intravenous (i.v.) therapy ...
Jie-Ning Wang   +6 more
doaj   +1 more source

Efficacy and safety of abciximab in diabetic patients who underwent percutaneous coronary intervention with thienopyridines loading: a meta-analysis. [PDF]

open access: yesPLoS ONE, 2011
BACKGROUND: It has been controversial whether abciximab offered additional benefits for diabetic patients who underwent percutaneous coronary intervention (PCI) with thienopyridines loading.
Yihua Wu   +6 more
doaj   +1 more source

Phase I and Phase II Therapies for Acute Ischemic Stroke: An Update on Currently Studied Drugs in Clinical Research. [PDF]

open access: yes, 2017
Acute ischemic stroke is a devastating cause of death and disability, consequences of which depend on the time from ischemia onset to treatment, the affected brain region, and its size.
Akyol, Onat   +6 more
core   +8 more sources

Intravenous abciximab as a rescue therapy for immediate reocclusion after successful mechanical thrombectomy in acute ischemic stroke patients

open access: yesPlatelets, 2022
Immediate reocclusion after mechanical thrombectomy (MT) for acute ischemic stroke (AIS) is a rare but devastating condition associated with poor functional outcome.
François Delvoye   +19 more
doaj   +1 more source

Alveolar Hemorrhage during Abciximab Infusion

open access: yesJournal of Tehran University Heart Center, 2021
Not ...
Yavuzer Koza   +3 more
doaj   +1 more source

Mechanical clot dissolution technique for surgical clip-related occlusions: An emergent triple-step approach

open access: yesBrain Circulation, 2021
Cerebral ischemia following clipping of cerebral aneurysms constitutes major cause of morbidity and mortality. Clip-related injury to vessel, postoperative clip rotation, prolonged temporary occlusion, intraoperative rupture, and vasospasm are some ...
Chirag Jain   +3 more
doaj   +1 more source

Quantitative structural mechanobiology of platelet-driven blood clot contraction. [PDF]

open access: yes, 2017
Blood clot contraction plays an important role in prevention of bleeding and in thrombotic disorders. Here, we unveil and quantify the structural mechanisms of clot contraction at the level of single platelets.
Alber, Mark S   +3 more
core   +2 more sources

Bilateral subconjunctival hemorrhage secondary to abciximab use: case report

open access: yesSão Paulo Medical Journal, 2017
CONTEXT: There are no reports on cases of subconjunctival hemorrhage due to use of glycoprotein IIb/IIIa inhibitors. In this report, we present the case of a patient with bilateral subconjunctival hemorrhage after receiving abciximab.
Selim Kul, Muhammet Raşit Sayın
doaj   +1 more source

Home - About - Disclaimer - Privacy